Organization
Les Laboratoires Servier SAS
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Les Laboratoires Servier SAS
... Taiho Oncology, Inc. and Servier today announced clinical data for LONSURF® (trifluridine and tipiracil) for the treatment ...
... Servier and Treventis announce strategic research partnership in targeting misfolded proteins implicated in ...
... cardiovascular, metabolic and renal diseases as well as selected targets in oncology. Servier and Novartis have also extended their collaboration to co-develop and commercialize anti-Mcl-1 ...
... in autoimmune diseases. OSE Immunotherapeutics has signed a license option agreement with Servier in December 2016 for the development and commercialization of OSE-127. Under this ...
... to plan having secured a EUR1m milestone from the third collaboration with Servier (as recently announced) as well as two new collaborations, including one recently ...
... plan having secured a EUR 1m milestone from the third collaboration with Servier (as recently announced) as well as two new collaborations, including one recently ...
... the sum will be fairly small, at least in the near term. Servier paid €2 million ($2.4 million) upfront and committed more in fees, milestones ...
... Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS)(NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: ...
... the drugs it left behind in its acquisition of Actelion. Cellectis named Servier’s former director of oncology R&D as its CMO. Bayer posted data on ...
... Vernalis PLC (LSE: VER) 6 December 2017 LSE: VER Vernalis and Servier Achieve Research Milestone in Third Oncology Collaboration Vernalis plc and Servier today ...
... of R&D. The appointment sees the former director of oncology R&D at Servier return to the industry after a spell directing the cancer immunotherapy program ...
... TALEN gene-edited, allogeneic CAR T product candidate in ALL patients,exclusively licensed to Servier Preliminary results of the first-in-human clinical trials of UCART19 will be presented ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... gene-edited, allogeneic CAR T product candidate in ALL patients, exclusively licensed to Servier Preliminary results of the first-in-human clinical trials of UCART19 will be presented ...
... and continued progression of lead assets under our alliances with AstraZeneca and Servier in respiratory disease and immuno-oncology," said Stephen S. Yoder, President and CEO ...
... and continued progression of lead assets under our alliances with AstraZeneca and Servier in respiratory disease and immuno-oncology," said Stephen S. Yoder, President and CEO ...
... Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Alternext: ALCLS - Nasdaq: CLLS), today ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS)(NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), ...
... Servier and GeNeuro (Euronext Paris: CH0308403085 - GNRO) announced today post hoc analyses ...
... Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase2b ...
... Servier has established a 3-year strategic research alliance with Harvard University to support ...
... Servier CDMO, the contract development and manufacturing organization (CDMO) division of Servier, today ...
... patients having completed CHANGE-MS, is fully financed by and fully recharged to Servier, and as a result does not burden our income statement or cash ...
... Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO) and Servier announced today that 6-month data from the CHANGE-MS Phase2b study will be ...
Want to see the full history on Les Laboratoires Servier SAS? Upgrade to RelSci Pro now!
Start My Free Trial